Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Finding key to cancer drug Gleevec's limitations

06.08.2009
Study offers path to improve breakthrough drug's action against chronic myeloid leukemia

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.

Leukemia-initiating cells are able to live below the drug's radar and enable the disease to recur in most cases after treatment stops, the researchers report in the August issue of Cancer Cell.

The researchers already are using their findings to test combinations of imatinib and other drugs to find ways to sensitize the leukemia-initiating cells to imatinib and enhance its power.

Context

Imatinib, now the standard first-line treatment for chronic myeloid leukemia or CML, has prolonged lives, but does not keep many patients from eventually moving into the disease's later, more severe stages.

Until imatinib was introduced in 2001, people with CML faced a grim prognosis, with few surviving five years after diagnosis unless they received bone marrow transplants. Imatinib has reversed that prospect, allowing 95 percent of people with CML to survive five years.

Yet it soon became clear that the disease almost always returns without maintenance treatments of imatinib. Imatinib treatment cures the disease in at best 5 percent of cases. Maintenance treatments are a concern, because the drug can cause side effects such as extreme fatigue, nausea, diarrhea and muscle pain. These force 15 percent of cancer patients to stop taking imatinib; some then undergo bone marrow transplants, the only treatment known to cure CML.

Imatinib, one of several targeted cancer therapies developed in recent years, inhibits certain enzymes associated with mutated genes that are involved in CML. Cancer researchers have suspected – but have not known until now – that certain cells that set events in motion toward CML are able to resist the drug.

"The mouse model we have developed for CML allows us to identify, understand and target the tumorigenic cell," says Theodora Ross, M.D., Ph.D., associate professor of internal medicine at U-M and senior author of the study. Developing a mouse model that closely reproduces the progression of human CML was a 10-year process.

CML is a slowly progressing disease in which too many of certain white blood cells are made in the bone marrow. It is also called chronic granulocytic leukemia or chronic myelogenous leukemia. An estimated 5,050 men and women will be diagnosed with chronic myeloid leukemia in 2009, and 470 will die of the disease, according to the National Cancer Institute.

Implications

Ross says that the study findings point to a new goal in CML treatment: to find ways to make imatinib specifically kill the leukemia-initiating cells that at present remain unaffected by the drug.

She and her team are currently testing several two-drug combinations using their mouse model. Imatinib is being combined either with interferon, rapamycin (also known as sirolimus), arsenic or GM-CSF (marketed as Neupogen). They hope to find combinations that will make the initiating cells more vulnerable to imatinib's action. If successful in mice, the combined therapy eventually can be tested in people.

Other authors of the study include: Katherine I. Oravecz-Wilson, Steven T. Philips, and Ömer H. Yilmaz, co-first authors; Heather M. Ames, Lina Li, Brendan D. Crawford, Alice M. Gauvin, and Sean J. Morrison, Ph.D., all in the U-M Department of Internal Medicine; Peter C. Lucas, M.D., and Kajal Sitwala, M.D., Ph.D., U-M Department of Pathology; and James R. Downing, M.D., Department of Pathology, St Jude Children's Research Hospital, Memphis, TN.

Funding for the study came from the National Institutes of Health, the Leukemia & Lymphoma Society and the Burroughs Wellcome Fund.

A clinical trial is not currently open and will not likely happen for several years. For information on current treatment options, call the U-M Cancer AnswerLine at 800-865-1125.

Citation: Cancer Cell, Vol. 16, Issue 2, Aug. 4, 2009

Anne Rueter | EurekAlert!
Further information:
http://www.umich.edu

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

Im Focus: Autonomous 3D scanner supports individual manufacturing processes

Let’s say the armrest is broken in your vintage car. As things stand, you would need a lot of luck and persistence to find the right spare part. But in the world of Industrie 4.0 and production with batch sizes of one, you can simply scan the armrest and print it out. This is made possible by the first ever 3D scanner capable of working autonomously and in real time. The autonomous scanning system will be on display at the Hannover Messe Preview on February 6 and at the Hannover Messe proper from April 23 to 27, 2018 (Hall 6, Booth A30).

Part of the charm of vintage cars is that they stopped making them long ago, so it is special when you do see one out on the roads. If something breaks or...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Fingerprints of quantum entanglement

16.02.2018 | Information Technology

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers

16.02.2018 | Health and Medicine

Hubble sees Neptune's mysterious shrinking storm

16.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>